Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Boehringer Ingelheim
Express Scripts
Baxter
McKinsey

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD5363

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug AZD5363?

AZD5363 is an investigational drug.

There have been 24 clinical trials for AZD5363. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are AstraZeneca, Cancer Research UK, and Royal Marsden NHS Foundation Trust.

There are fourteen US patents protecting this investigational drug and one hundred and fifty-five international patents.

Recent Clinical Trials for AZD5363
TitleSponsorPhase
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerParexelPhase 1
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerAstraZenecaPhase 1
Phase I Study of AZD5363 + Olaparib + Durvalumab (MEDI4736) in Patients With Advanced or Metastatic Solid Tumor MalignanciesNational University Hospital, SingaporePhase 1

See all AZD5363 clinical trials

Clinical Trial Summary for AZD5363

Top disease conditions for AZD5363
Top clinical trial sponsors for AZD5363

See all AZD5363 clinical trials

US Patents for AZD5363

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD5363   Start Trial Polymeric nanoparticles and methods of making and using same Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)   Start Trial
AZD5363   Start Trial Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD5363   Start Trial Protein kinase B inhibitors AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD5363   Start Trial Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor AstraZeneca AB (Sodertaje, SE)   Start Trial
AZD5363   Start Trial Chemical compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD5363   Start Trial Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]py- rimidin-4-yl)piperidine-4-carboxamide AstraZeneca AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD5363

Drugname Country Document Number Estimated Expiration Related US Patent
AZD5363 European Patent Office 3119395 2034-03-17   Start Trial
AZD5363 World Intellectual Property Organization (WIPO) 2015142605 2034-03-17   Start Trial
AZD5363 Australia 2013204533 2032-04-17   Start Trial
AZD5363 Canada 2869936 2032-04-17   Start Trial
AZD5363 China 104203953 2032-04-17   Start Trial
AZD5363 European Patent Office 2847194 2032-04-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Express Scripts
Dow
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.